Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 53 citing Rubin: Ursodiol for hepatobiliary disorders. (0.11 sec) 

Ursodeoxycholic acid [] mechanisms of action and clinical use in hepatobiliary …


KN Lazaridis, GJ Gores, KD Lindor - Journal of hepatology, 2001 - Elsevier
In 1902, Hammarsten first reported the presence of an unknown bile acid in the bile of the polar
bear that he called 'ursocholeinic acid' [2]. At that time, given the lack of knowledge on steroid
compounds, Hammarsten was unable to describe the chemical structure of this novel bile ...
Cited by 170 - Related articles - BL Direct - All 7 versions

Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological …

- sinoas.com [PDF] 
E Ros - Atherosclerosis, 2000 - Elsevier
Triglycerides and cholesterol are important biological lipids, and their excessive intake in the
diet is relevant to the development of two prevalent cardiovascular risk factors, obesity and
hypercholesterolemia. Because most lipids are essentially water-insoluble molecules, ...
Cited by 99 - Related articles - All 8 versions

of ursodeoxycholic acid in chronic liver diseases


M Trauner, IW Graziadei - Aliment Pharmacol Ther, 1999 - interscience.wiley.com
Ursodeoxycholic acid (ursodiol) is a non-toxic, hydrophilic bile acid used to treat predominantly
cholestatic liver disorders. Better understanding of the cellular and molecular mechanisms of
action of ursodeoxycholic acid has helped to elucidate its cytoprotective, anti-apoptotic, ...
Cited by 86 - Related articles - BL Direct - All 3 versions

Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune …


AJ Czaja, HA Carpenter, KD Lindor - Hepatology, 1999 - interscience.wiley.com
To evaluate the efficacy of ursodeoxycholic acid as adjunctive therapy in type 1 autoimmune
hepatitis, 37 patients who had experienced treatment failure, repeated relapse, or incomplete
response were randomized to ursodeoxycholic acid (13-15 mg/kg daily) or placebo for 6 ...
Cited by 80 - Related articles - BL Direct - All 3 versions

Apoptosis in diseases of the liver


MG Neuman - Critical reviews in clinical laboratory sciences, 1998 - informahealthcare.com
ABSTRACT: Apoptosis, or programmed cell death, and the elimination of apoptotic cells are
crucial factors in the maintenance of liver health Apoptosis allows hepatocytes to die without
provoking a potentially harmful inflammatory response In contrast to necrosis, apoptosis ...
Cited by 70 - Related articles - BL Direct - All 8 versions

Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic …

- kmuk.lt [PDF] 
J Kondrackiene, U Beuers, L Kupcinskas - Gastroenterology, 2005 - Elsevier
Background & Aims: Treatment of intrahepatic cholestasis of pregnancy with ursodeoxycholic
acid appears promising, but data are limited so far. The aim of this randomized study was to evaluate
the efficacy and safety of ursodeoxycholic acid in comparison with cholestyramine. ...
Cited by 68 - Related articles - All 25 versions

Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic …


WF Balistreri - Journal of pediatric gastroenterology and nutrition, 1997 - journals.lww.com
Clinicians have been frustrated by their inability to effectively treat infants and children with severe
hepatobiliary disease due to biliary atresia, neonatal hepatitis, or various forms of intrahepatic
cholestasis, including cystic fibrosis-associated liver disease. Affected patients are ...
Cited by 76 - Related articles - BL Direct - All 3 versions

Ursodeoxycholic acid therapy in hepatobiliary disease


KV Kowdley - The American journal of medicine, 2000 - Elsevier
Ursodeoxycholic acid is a hydrophilic bile acid that under normal circumstances represents a
small fraction of the bile acid pool in humans. It is effective in dissolving cholesterol gallstones
in appropriately selected patients. Ursodeoxycholic acid improves serum alkaline ...
Cited by 66 - Related articles - BL Direct - All 10 versions

Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N …


D Graf, AK Kurz, R Fischer, R Reinehr, D Häussinger - Gastroenterology, 2002 - Elsevier
TLCS induced activation of caspases 8, 9, and 3 and hepatocyte apoptosis. These effects were
abolished by TUDC in a PI 3-kinase-/ protein kinase B (PKB)-, p38 MAPK , and extracellular
signal-regulated kinase-2 (Erk-2)-independent manner. These protein kinases were ...
Cited by 59 - Related articles - BL Direct - All 12 versions

Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic …

- rug.nl [PDF] 
MH Schoemaker, WM Gommans, LC de la Rosa, M … - Journal of hepatology, 2003 - Elsevier
Results: Limited hepatocyte apoptosis and an increased expression of NF-κB-regulated
anti-apoptotic genes A1 and cIAP2 were detected in cholestatic rat livers. Bcl-2 expression was
restricted to bile duct epithelium. In contrast to TCDCA and TUDCA, GCDCA induced ...
Cited by 55 - Related articles - All 19 versions


Result Page: 

1

2

3

4

5

6

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google